Fundraising FoxCivatech Oncology
Durham, US · North Carolina corporation
Find your way into Civatech Oncology
Sign up to see every warm intro you have to Civatech Oncology
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Civatech Oncology team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CivaTech Oncology develops polymer-encapsulated low dose rate brachytherapy devices—including CivaSheet, CivaString, and CivaDerm—used by radiation oncologists to deliver targeted radiation therapy for solid tumors such as prostate, pancreatic, and skin cancers. The company designs and commercializes FDA-cleared, bioabsorbable radiation therapy products for cancer treatment.
Founders & leadership
ST
Suzanne Troxler BabcockFounder
Board
CM
Carlton MidyetteBoard director
RJ
Robert J. Greczyn, Jr.Board director
DC
Delwin CoufalBoard director
TL
Tempe LampeBoard director
Reported raises · per SEC filings
Form D private placements$13.2M disclosed across 7 rounds · 2012–2021
▶$7.9MraisedNov 2021 · 47 investors · Other Health CareRule 506(b)
▶$7.9MraisedNov 2021 · 47 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- William PullyDirector
- Herb KuhnDirector
- Carlton MidyetteDirector
- James A. BeckDirector
- Tempe LampeDirector
- Suzanne Troxler BabcockExecutive Officer, Director
- Offering amount
- $15.2M
- Amount sold
- $7.9M
- Sales commissions
- $159K
- Placement agents
- EuroConsult, Inc.
- First sale
- Nov 2021
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$15KraisedDec 2017 · 1 investors · Other Health CareRule 506(b)
▶$15KraisedDec 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert J. Greczyn, Jr.Director
- Tempe LampeDirector
- William PullyDirector
- Suzanne Troxler BabcockExecutive Officer, Director
- James A. BeckDirector
- Carlton MidyetteDirector
- Offering amount
- $2M
- Amount sold
- $15K
- First sale
- Dec 2017
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$916.1KraisedAug 2017 · 9 investors · Other Health CareRule 506(b)
▶$916.1KraisedAug 2017 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Tempe LampeDirector
- Carlton MidyetteDirector
- James A. BeckDirector
- Robert J. Greczyn, Jr.Director
- William PullyDirector
- Suzanne Troxler BabcockExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $916.1K
- First sale
- Jul 2017
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$2.7MraisedDec 2016 · 28 investors · Other Health CareRule 506(b)
▶$2.7MraisedDec 2016 · 28 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Tempe LampeExecutive Officer
- Robert J. GreczynDirector
- Carlton MidyetteDirector
- Suzanne Troxler BabcockExecutive Officer, Director
- Delwin CoufalDirector
- Offering amount
- $2.7M
- Amount sold
- $2.7M
- First sale
- Sep 2015
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$10KraisedAug 2016 · 1 investors · Other Health CareRule 506(b)
▶$10KraisedAug 2016 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Suzanne Troxler BabcockExecutive Officer, Director
- Carlton MidyetteDirector
- Robert J. Greczyn, Jr.Director
- Delwin CoufalDirector
- Tempe LampeDirector
- Offering amount
- $2M
- Amount sold
- $10K
- First sale
- Jul 2016
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$1.5MraisedJul 2014 · 16 investors · Other Health CareRule 506(b)
▶$1.5MraisedJul 2014 · 16 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Suzanne Troxler BabcockExecutive Officer, Director
- Tempe LampeExecutive Officer
- Robert J. GreczynDirector
- Delwin CoufalDirector
- Offering amount
- $2M
- Amount sold
- $1.5M
- First sale
- Apr 2014
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$75KraisedMar 2012 · 2 investors · Other Health CareRule 506(b)
▶$75KraisedMar 2012 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Suzanne T. BabcockExecutive Officer, Director
- Robert J. Greczyn, Jr.Director
- Tempe LampeDirector
- Delwin CoufalDirector
- Offering amount
- $600K
- Amount sold
- $75K
- First sale
- Mar 2012
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
KiyatecKIYATEC develops 3D Predict, a tumor-specific testing platform that uses patient-derived tumor cells to predict how individual cancers respond to therapies. It serves oncologists and cancer patients in the precision oncology and diagnostics space.
Rarecyte
ItnonlineImaging Technology News is a trade publication that reaches over 34,000 radiology, radiation oncology, women's health, and nuclear medicine professionals with editorial content and product comparison tools. The publication serves as a primary resource for healthcare technology purchasing decisions within medical imaging specialties.
CelcuityCelcuity is a commercial-stage biotechnology company developing targeted cancer therapies for tumors involving the PAM (PI3K/AKT/mTOR) pathway, including breast, prostate, lung, endometrial, colon, and ovarian cancers. Its lead candidate, gedatolisib, targets all Class I PI3K isoforms and the mTORC1 and mTORC2 complexes and is being evaluated across multiple oncology clinical programs.
BioCyticsBioCytics conducts translational cancer research, including a project with UNC Charlotte and Carolina BioOncology Institute to study the "dark genome" of cancer cells to identify sequences involved in tumor growth, immune response, and treatment response. Its work spans cell therapy, neoantigens, tumor infiltrating lymphocytes, and clinical research informatics.
Dialectic TherapeuticsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Companies working in the same space as Civatech Oncology.
Non-dilutive funding · 7 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $296.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $299.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $999K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $199.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Civatech Oncology do?
- CivaTech Oncology develops polymer-encapsulated low dose rate brachytherapy devices—including CivaSheet, CivaString, and CivaDerm—used by radiation oncologists to deliver targeted radiation therapy for solid tumors such as prostate, pancreatic, and skin cancers. The company designs and commercializes FDA-cleared, bioabsorbable radiation therapy products for cancer treatment.
- Who founded Civatech Oncology?
- Civatech Oncology was founded by Suzanne Troxler Babcock.
- How much funding has Civatech Oncology raised?
- Civatech Oncology has disclosed $13.2M raised across 7 rounds.
- Where is Civatech Oncology headquartered?
- Civatech Oncology is headquartered in Durham, US.